World Congress on Biosensors 2014

World Congress on Biosensors 2014
Biosensors 2014

Thursday, 23 February 2012

Always see the dark and the bright with Olympus HDR imaging

Olympus has launched the latest version of its highly successful OLYMPUS Stream software family for industrial and material science microscopy applications. Building on the renowned functionality of previous iterations, OLYMPUS Stream 1.7 with High Dynamic Range (HDR) enables you to capture perfectly illuminated images, even when high material contrast occurs. All cameras have a limited dynamic range, meaning that they can only capture so much contrast within a single shot. Applications where the in-depth analysis of contrasting materials is required, such as the quality control of products built using a mix of light-reflecting and light-absorbing components, can therefore be problematic. The new HDR algorithms of OLYMPUS Stream 1.7 produce final images with optimised contrast, so that you can visualise the brightest and darkest areas of a specimen, in a single image. This makes it ideal for applications where you need to analyse metallurgic microstructures, printed circuit boards, or composite components.
As an integral part of the OLYMPUS Stream 1.7 software, HDR automatically acquires a series of images at varying exposure times. It then merges sections of the different images together, producing a final image in which both the bright and dark sections of the sample are optimally exposed, ensuring every important detail is visible. The whole process takes mere seconds, and when combined with the Extended Focal Imaging (EFI) and Multiple Image Alignment (MIA) functions, you can capture a broad range of images, while significantly simplifying and speeding up the entire process.
When combined with a host of other exciting new features, HDR makes OLYMPUS Stream 1.7 the most powerful imaging and analysis software available to date.
The OLYMPUS Stream family
The OLYMPUS Stream software is designed to make advanced analysis and archiving options easy to perform for everyone, regardless of expertise. It is available in four versions: Start, Basics, Essentials and Motion. Each version incorporates the same intuitive user interface, so when upgrading to a higher level package, you are supplied with the familiar on-screen appearance, but including new functionality. By displaying only the required features at any given time, OLYMPUS Stream provides the ideal level of complexity to effectively meet any requirements. Analysis options include all measurement types, such as lengths, angles, counting, and phase analysis based on threshold values. In addition, the OLYMPUS Stream Motion platform can be upgraded to provide access to a large number of more in-depth, application-specific analyses via the purchase of additional OLYMPUS Stream Solutions.
Please contact:
OLYMPUS EUROPA HOLDING GMBH
Katja Ansmann
Marketing Communications Manager
Tel: +49 40 2 37 73 - 5913
Fax: +49 40 2 37 73 - 4656
E-mail: microscopy@olympus-europa.com
www.microscopy.olympus.eu

Dr. Tuulia Hyotylainen wins HTC-12 Award

Dr. Tuulia Hyotylainen of the VTT Technical Research Centre of Finland has won the HTC-12  Award for her state-of-the-arty presentation - an abstract of which follows below:



Comprehensive metabolic profiling by multidimensional and hyphenated chromatographic techniques
Tuulia Hyötyläinen
Sirkku Jäntti1, Maarit Kivilompolo1, Artturi Koivuniemi1, Ismo Mattila1, Tuulikki Seppänen-Laakso1, Heli Nygren1, Kirsi Pietiläinen,2,3 Hannele Yki-Järvinen4, Matej Orešič1, Tuulia Hyötyläinen1

1VTT Technical Research Centre of Finland, Espoo, FI-02044 VTT, Finland
2 Department of Psychiatry, Helsinki University Central Hospital, Helsinki, Finland
3 Department of Public Health, University of Helsinki, Finland
4Department of Medicine, Division of Diabetes, Helsinki, Finland

Obesity is associated with multiple adverse health effects and a high risk of developing metabolic and cardiovascular diseases, such as diabetes and non-alcoholic fatty liver disease (NALFD). Obesity causes severe changes in the metabolic balance, however, the exact mechanisms by which obesity contributes to various disturbances is poorly characterised. Here, we have studied several key aspects of the metabolic mechanisms in obesity, with study groups including both large clinical cohorts, and small targeted group of individuals, such as study monozygotic twins discordant for obesity, and obese individual undergoing hepatic venous catheterization.  Metabolic profiling of serum, lipoprotein fractions as well as adipose tissue biopsies were utilised to allow detailed characterization of the metabolic processes associated with obesity. For the detailed characterisation of changes in the metabolic profiles, both non-targeted and targeted methodologies, utilising several chromatographic methodologies combined with mass spectrometry were applied. The global lipid profiles in serum and adipose tissue were profiled with UPLC-QTOFMS, while polar small metabolites were determined by GCxGC-TOFMS. Targeted methods using UPLC-QQQMS were developed for the analysis of bile acids in serum and eicosanoids and steroids in adipose tissue. Information gathered from these studies was used for modelling as well as molecular dynamics simulations. The results show that in obese individuals, adaptation of adipocyte membranes to adipose tissue expansion associates with positive energy balance, potentially leading to higher vulnerability to inflammation in acquired obesity.  Also, we have identified serum markers for NALFD and characterised the effect of liver fat on several key metabolic pathways in liver metabolism.

Wednesday, 22 February 2012

Just Published: Journal of Pharmaceutical and Biomedical Analysis

A new issue of this journal has just been published. To see abstracts of the papers it contains (with links through to the full papers) click here:
Journal of Pharmaceutical and Biomedical Analysis
http://rss.sciencedirect.com/publication/science/5266
Selected papers from the latest issue:

Pharmacokinetics and disposition study of calf thymus DNA in rats by applyingH-labelling method

20 February 2012, 22:51:34
Publication year: 2012
Source: Journal of Pharmaceutical and Biomedical Analysis, Available online 20 February 2012
Shuoye Yang, Qiuyang Zhang, Jiayin Chen, Deen Han, Di Zhao, ...
A tritium(H)-labelling method with high specificity was established to investigate the pharmacokinetics and disposition of the Calf thymus DNA(ctDNA) in rats. The plasma pharmacokinetics, tissue distribution, mass balance and excretion was characterized in SD rats, respectively. Rats were injected i.v. with radiolabeled ctDNA with the dose of 40 μCi/kg in each independent experiment.H-labeled ctDNA was eliminated rapidly in plasma, with the half-life estimated from 9-13 hours and preferentially accumulated in liver and lung, its concentration in all the tissues investigated decreased to very low level after 24 hours. ctDNA exhibited 80.8% accumulative recovery, excretion of radiolabel in urine and bile was nearly complete by 72 hours, which shown as the main excretion pathways, and the total recovery of excretion reached 77.9% within three days. In conclusion, ctDNA was rapidly eliminated in plasma and would not accumulate in tissues, parent ctDNA and its radioactive metabolites can be recovered almost completely in schedule time. All the results indicated that the in vitro use of ctDNA is safe and will not bring out potential risk.

Highlights

► A tritium(H)-labelling method with high specificity was established; ► The pharmacokinetics and disposition of the ctDNA in rats were investigated in detail; ► Results showed that ctDNA was safe for therapeutic use.

Risk analysis of analytical validations by probabilistic modification of FMEA

20 February 2012, 22:51:34
Publication year: 2012
Source: Journal of Pharmaceutical and Biomedical Analysis, Available online 20 February 2012
D.M. Barends, M.T. Oldenhof, M.J. Vredenbregt, M.J. Nauta
Risk analysis is a valuable addition to validation of an analytical chemistry process, enabling not only detecting technical risks, but also risks related to human failures. Failure Mode and Effect Analysis (FMEA) can be applied, using a categorical risk scoring of the occurrence, detection and severity of failure modes, and calculating the Risk Priority Number (RPN) to select failure modes for correction. We propose a probabilistic modification of FMEA, replacing the categorical scoring of occurrence and detection by their estimated relative frequency and maintaining the categorical scoring of severity. In an example, the results of traditional FMEA of a Near Infrared (NIR) analytical procedure used for the screening of suspected counterfeited tablets are re-interpretated by this probabilistic modification of FMEA. Using this probabilistic modification of FMEA, the frequency of occurrence of undetected failure mode(s) can be estimated quantatively, for each individual failure mode, for a set of failure modes, and the full analytical procedure.

Highlights

► FMEA is a valuable addition to analytical validation ► Traditional FMEA is modified by replacing categorical scores by probabilities ► Probabilistic modification of FMEA has added values ► Frequencies of occurence of undetected failure modes are now quantified

Editorial Board

19 February 2012, 00:52:41
Publication year: 2012
Source: Journal of Pharmaceutical and Biomedical Analysis, Volume 62, 25 March 2012, Pages CO2
[No author name available]

Acetylcholinesterase capillary enzyme reactor for screening and characterization of selective inhibitors

19 February 2012, 00:52:41
Publication year: 2012
Source: Journal of Pharmaceutical and Biomedical Analysis, Available online 18 February 2012
Joyce Izidoro da Silva, Marcela Cristina de Moraes, Lucas Campos Cursino Vieira, Arlene Gonçalves Corrêa, Quezia Bezerra Cass, ...
The aim of the present work is to report on the optimized preparation of capillary enzyme reactors (ICERs) based on acetylcholinesterase (AChE, E. C. 3.1.1.7), for the screening of selective inhibitors. The AChE-ICERs were prepared by using the homobifunctional linker glutaraldehyde through Schiff base linkage. The enzyme was anchored onto a modified fused silica capillary and employed as an LC biochromatogaphy column for online studies, with UV-Vis detection. Not only did the tailored AChE-ICER result in maintenance of the activity of the immobilized enzyme, but it also significantly improved the stability of the enzyme in the presence of organic solvents. In addition, the kinetic studies demonstrated that the enzyme retained its activity with high stability, preserving its initial activity over 10 months. The absence of non-specific matrix interactions, immediate recovery of the enzymatic activity, and short analysis time were the main advantages of this AChE-ICER. The use of AChE-ICER in the ligands recognition assay was validated by evaluation of four known reversible inhibitors (galanthamine, tacrine, propidium, and rivastigmine), and the same order of inhibitory potencies described in the literature was found. The immobilized enzyme was utilized in the screening of 21 coumarin derivatives. In this library, two new potent inhibitors were identified: coumarins20(IC5017.14 ± 3.50 μM) and21(IC506.35 ± 1.20 μM), which were compared to the standard galanthamine (IC5012.68 ± 2.40 μM). Considering the high inhibitory activities of these compouds, with respect to the AChE-ICER, the mechanism of action was investigated. Both coumarins20and21exhibited a competitive mechanism of action, furnishing Kivalues of 8.04 ± 0.18 and 2.67 ± 0.18 μM, respectively. The results revealed that the AChE-ICER developed herein represents a useful tool for the biological screening of inhibitor candidates and evaluation of action mechanism.

Graphical abstract


image

Highlights

► Acetylcholinesterase from Electric eel was immobilized onto a fused silica capillary resulting AChE-ICER. ► AChE-ICER was employed as an LC biochromatography column in on line inhibitor studies. ► Selected compounds20(IC50= 17.14 ± 3.50 μM and Ki= 8.04 ± 0.18) and21(IC50= 6.35 ± 1.20 μM and Ki= 2.67 ± 0.18 μM). ► Standard galanthamine (IC50= 12.68 ± 2.40 μM and Ki= 10.90 ± 0.51 μM). ► The obtanid data suggest the applicability of the method developed herein for the identification of new ligands.

Simultaneous determination of antidementia drugs in human plasma: Procedure transfer from HPLC-MS to UPLC-MS/MS

19 February 2012, 00:52:41Go to full article
Publication year: 2012
Source: Journal of Pharmaceutical and Biomedical Analysis, Available online 18 February 2012
Muriel Noetzli, Nicolas Ansermot, Maria Dobrinas, Chin B. Eap
A previously developed high performance liquid chromatography mass spectrometry (HPLC-MS) procedure for the simultaneous determination of antidementia drugs, including donepezil, galantamine, memantine, rivastigmine and its metabolite NAP 226-90, was transferred to an ultra performance liquid chromatography system coupled to a tandem mass spectrometer (UPLC-MS/MS). The drugs and their internal standards ([H7]-donepezil, [C,H3]-galantamine, [C2,H6]-memantine, [H6]-rivastigmine) were extracted from 250 μL human plasma by protein precipitation with acetonitrile. Chromatographic separation was achieved on a reverse phase column (BEH C18 2.1 × 50 mm; 1.7 μm) with a gradient elution of an ammonium acetate buffer at pH 9.3 and acetonitrile at a flow rate of 0.4 mL/min and an overall run time of 4.5 min. The analytes were detected on a tandem quadrupole mass spectrometer operated in positive electrospray ionization mode, and quantification was performed using multiple reaction monitoring. The method was validated according to the recommendations of international guidelines over a calibration range of 1-300 ng/mL for donepezil, galantamine and memantine, and 0.2-50 ng/mL for rivastimgine and NAP 226-90. The trueness (86-108%), repeatability (0.8-8.3%), intermediate precision (2.3-10.9%) and selectivity of the method were found to be satisfactory. Matrix effects variability was inferior to 15% for the analytes and inferior to 5% after correction by internal standards. A method comparison was performed with patients’ samples showing similar results between the HPLC-MS and UPLC-MS/MS procedures. Thus, this validated UPLC-MS/MS method allows to reduce the required amount of plasma, to use a simplified sample preparation, and to obtain a higher sensitivity and specificity with a much shortened run-time.

Highlights

► Four antidementia drugs were simultaneously quantified by UPLC-MS/MS ► A procedure transfer from HPLC-MS to UPLC-MS/MS was carried out ► The new UPLC procedure is faster, more sensitive and more specific ► Validation showed good results concerning accuracy, precision and matrix effects ► A Passing-Bablok analysis was performed to compare the HPLC and UPLC procedures

Tentative identification of phase I metabolites of HU-210, a classical synthetic cannabinoid, by LC-MS/MS

19 February 2012, 00:52:41
Publication year: 2012
Source: Journal of Pharmaceutical and Biomedical Analysis, Available online 18 February 2012
Unyong Kim, Ming Ji Jin, Jaeick Lee, Sang Beom Han, Moon Kyo In, ...
(6aR, 10aR)-9-(Hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)-6a, 7, 10, 10a-tetrahydrobenzo [c]chromen-1-ol (HU-210) is a synthetic cannabinoid, with a classical cannabinoid structure similar to Δ-tetrahydrocannabinol (Δ-THC). In this study, thein vitrometabolism of HU-210 was investigated in human liver microsomes to characterize associated phase I metabolites. HU-210 was incubated with human liver microsomes, and the reaction mixture was analyzed using LC-MS/MS. HU-210 was metabolized in human liver microsomes, yielding about 24 metabolites. These metabolites were structurally characterized on the basis of accurate mass analyses and MS/MS fragmentation patterns. The major metabolic route for HU-210 was oxygenation. Metabolites M1–M7 were identified as mono-oxygenated metabolites; M8–M15, mono-hydroxylated metabolites; M16–M20, di-oxygenated metabolites; and M21–M24, di-hydroxylated metabolites. These results provide evidence forin vivoHU-210 metabolism, and they may be applied to the analysis of HU-210 and its relevant metabolites in biological samples.

Highlights

►In vitrometabolism of HU-210 was investigated in human liver microsomes ► The chemical structures of HU-210 metabolites were characterized using LC-MS/MS ► A total of 24 metabolites were detected ► The major metabolic route for HU-210 was oxygenation.

FOSS releases new features for Vision

FOSS NIRSystems, Inc. has introduced Service Pack 7 (SP 7) for Vision 3.50. At the same time we are also releasing version 2.0 of Digital Protocols for Vision, which replaces all previous versions.

Vision is a software package specifically designed for use with the FOSS NIRSystems Near-Infrared (NIR) laboratory and process analyzers. Vision 3.50 SP 7 is a cumulative service pack and offers support for the latest NIR laboratory and process hardware.

If you are a current user of the FOSS Vision software, please contact us for more information and/or a complete list of new features appearing in version 3.50 SP 7.

The FOSS Vision software is 21 CFR Part 11 compliant and supports PAT through numerous process analysis options and process communication capabilities. The software has an extensive security system with multiple access levels, secure data archiving and report generation as well as database and spreadsheet compatibility. Vision comes with a user-friendly electronic manual with tutorials and data for self taught hands-on method development and software operation.

Sports Drug Testing Lab Accelerates Sample Preparation

Genevac has announced an applications report** that details how its miVac Duo sample concentrator has been used by a leading testing laboratory to develop a new sample preparation method to help curb sports doping.

Recent developments in applying mass spectrometry to proteomics means that it is becoming feasible for doping laboratories to routinely detect and confirm the abuse of peptide hormones by sportsmen and women. Using mass spectrometry to detect and confirm the abuse of peptide hormones is preferred to the use of immunoassay techniques as the methodology is able to positively differentiate between endogenous insulin and its synthetic analogues. To use LC-MS techniques to detect synthetic insulin however requires that samples are extracted and concentrated prior to analysis. This traditionally time consuming procedure requires at least one evaporation of a solution with high water content.

Using a miVac Duo sample concentrator the Australian Sports Drug Testing Lab was able to significantly improve their sample preparation method for synthetic insulin's in serum.  Using the miVac Duo - sample preparation times were reduced from several days to just 2 hours and better and more consistent recoveries were obtained than using the traditional nitrogen blow down evaporation method.

Affordably priced the miVac concentrator sets the standard for careful and speedy biological sample concentration and drying from a variety of sample formats including tubes, microplates and vials.  Compact in design - miVac concentrators feature built-in special methods for working with alcohols, water and water mixtures to improve performance and optimise concentration times.  Comprising three models of varying capacity each miVac concentrator features full LCD display with digital control and programming of time and temperature to minimise the chances of heat damage to your samples.  The miVac pressure controller helps further to optimise concentration through smoothing the onset of concentration and preventing sample splashing.  Offering unmatched performance, sample safety, versatility and ease-of-use - miVac is the first biological sample concentrator system with modules designed to work together and also look good.

For a copy of the applications report "Better Analysis of Insulin Analogues" please visit www.genevac.com/metabolism**. For further information on the miVac sample concentrator please contact Genevac now on +44-1473-240000 / salesinfo@genevac.co.uk (International) or +1-845-267-2211 / salesinfo@genevac.com (North America).

Tuesday, 21 February 2012

Just Published: Journal of Chromatography B

A new issue of this journal has just been published. To see abstracts of the papers it contains (with links through to the full papers) click here:
Selected papers from the latest issue:

LC-ESI-MS/MS determination of in vivo metabolites of almotriptan in rat plasma, urine and feces: Application to pharmacokinetics

20 February 2012, 22:50:09Go to full article
Publication year: 2012
Source: Journal of Chromatography B, Available online 20 February 2012
R. Nageswara Rao, K. Guruprasad, Ch. Gangu Naidu, B. Raju, R. Srinivas
A highly sensitive and specific liquid chromatography-electrospray ionization tandem mass spectrometric (LC-ESI-MS/MS) method for investigating the in vivo metabolites of almotriptan in rat plasma, feces and urine was developed. Chromatographic separation was achieved on a Lichrospher RP-18 column (250 × 4.6 mm, 5 μm), using 20 mM ammonium acetate (pH 3.5) and acetonitrile (60:40 v/v) as a mobile phase at 25 °C. MS/MS detection was performed by positive ion electrospray ionization using target ions atm/z336 [M + H], m/z368 &m/z282 [M + H]for almotriptan and its two metabolites, respectively. Two metabolitesviz., γ-aminobutyric acid and sulphonamide were detected in plasma as well as feces after 24 h of oral administration of almotriptan, while only γ-aminobutyric acid was found in urine. The method was sensitive with a lower limit of quantification of 1.43 ng/mL and linear over the range of 1.43-5000 ng/mL in plasma. The method was validated and successfully applied to a pharmacokinetic study of almotriptan in rat plasma using sumatriptan as an internal standard. The peak plasma concentration (Cmax) after 0.3 h of 5 mg/kg oral dose of almotriptan was determined to be 69.85 ng/mL.

Highlights

► Metabolite identification has been facilitated in high resolution LC-MS/MS. ► The method was successfully applied to study pharmacokinetics of almotriptan. ► Simple protein precipitation method was used for rat plasma in sample preparation. ► Good separation and resolution were obtained on Lichrospher RP-18 column.

Measurements of Polybrominated Diphenyl Ethers and Polychlorinated Biphenyls in a Single Drop of Blood

20 February 2012, 22:50:09Go to full article
Publication year: 2012
Source: Journal of Chromatography B, Available online 19 February 2012
Dasheng Lu, Dongli Wang, Ho Sai Simon Ip, Frank Barley, Bob Ramage, ...
A quantitative method that requires only small volume (50 μL) of blood sample has been developed for the determination of polybrominated diphenyl ethers (PBDEs) and polychlorinated biphenyls (PCBs). Target analytes in both plasma blood sample (DBSV) and dried blood spot (DBS) were analyzed by a gas chromatography/high resolution mass spectrometer (GC/HRMS). Measurements of standard reference materials by the developed method were in agreement with those certified values. Linear correlation coefficients were found to be 0.9985 and 0.9968 for DBS and DBSV analysis, respectively. Other analytical criteria, such as limits of detection, recoveries, precision, accuracy and linearity of the proposed method were also reported. From recovery studies, the addition of formic acid in the extraction solvent was found to be effective in extracting PBDEs and PCBs from filter paper. The PBDE and PCB levels in spiked DBS were monitored at room temperature for up to 30 days and the variations of target analytes were found to be insignificant. Our results suggest that DBS sampling technique is feasible for PBDE and PCBs biomonitoring in human population.

Highlights

► A method was developed and well validated to determine PCBs and PBDEs in a small volume (50 μL) of blood samples and in dry blood spots ► Measurements of PBDE and PCBs in dried blood spots have not been reported in the previous studies ► PCBs and PBDEs were measured in filter paper blanks from different manufacturing years (1987-2009). ► Levels of PBDE/PCB in dried blood spot samples did not show any changes during a period of 30 days.

Unique Products & Custom Services for Life Science Research

AMSBIO has announced that it will be displaying its latest innovative products for life science research at SLAS 2012 - one of the world's largest laboratory automation and screening trade shows and congresses.

At this important event AMSBIO will introduce cutting edge products for 3D culture using alvetex™, GMP grade extracellular matrix proteins for regenerative medicine and a range of unique products for glycobiology including proteoglycans, enzymes, assays and hyaluronic acid derivatives.

Visitors to Booth 1335 will have the chance to find out how AMSBIO can assist in their biomarker discovery programs. Using a range of custom services AMSBIO can design lentivirus, provide highly active and pure proteins for drug screening, develop peptides and antibodies as well as provide synthetic RNA and DNA controls.  Drawing upon the extensive experience of its staff - AMSBIO has established itself as a knowledgeable and responsive partner for the life science industry to outsource work to.

For further information please visit SLAS 2012 (www.slas2012.org) or contact AMSBIO LLC on +1-949-768-8365 or email info@amsbio.com